Chk1 Antibody (D-7): sc-377231
- Chk1 Antibody (D-7) is a mouse monoclonal IgG1 κ, cited in 11 publications, provided at 200 µg/ml
- raised against amino acids 1-476 representing full length Chk1 of human origin
- recommended for detection of Chk1 of mouse, rat and human origin by WB, IP, IF and ELISA
- See Chk1 (G-4): sc-8408 for Chk1 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG1 BP-HRP is the preferred secondary detection reagent for Chk1 Antibody (D-7) for WB applications. This reagent is now offered in a bundle with Chk1 Antibody (D-7) (see ordering information below).
QUICK LINKS
Chk1 Antibody (D-7) is a mouse monoclonal IgG1 antibody that detects Chk1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Chk1 plays a critical role in the cellular response to DNA damage, particularly during the G2 phase of the cell cycle, where Chk1 acts as a checkpoint regulator. By phosphorylating Cdc25C, Chk1 inhibits phosphatase activity, which is essential for preventing premature entry into mitosis in the presence of DNA damage. This function is vital for maintaining genomic stability and preventing the propagation of damaged DNA, which could lead to tumorigenesis. Additionally, Chk1′s ability to phosphorylate other proteins, such as Wee1, further underscores Chk1′s importance in cell cycle regulation and the intricate network of signaling pathways that ensure proper cell division. Anti-Chk1 antibody (D-7) is an invaluable tool for researchers studying cell cycle dynamics, DNA damage response mechanisms, and their implications in cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Chk1 Antibody (D-7) References:
- An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. | Jamil, S., et al. 2008. Mol Biol Cell. 19: 3212-20. PMID: 18495871
- Targeting the checkpoint kinase Chk1 in cancer therapy. | Merry, C., et al. 2010. Cell Cycle. 9: 279-83. PMID: 20023404
- Conformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage. | Han, X., et al. 2016. J Biol Chem. 291: 12951-9. PMID: 27129240
- Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. | Yu, X., et al. 2020. J Hematol Oncol. 13: 40. PMID: 32357935
- Jatrophane Diterpenoids from Euphorbia peplus as Multidrug Resistance Modulators with Inhibitory Effects on the ATR-Chk-1 Pathway. | Yang, Y., et al. 2021. J Nat Prod. 84: 339-351. PMID: 33443423
- RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. | Nunes, C., et al. 2022. Sci Adv. 8: eabn1382. PMID: 35857500
- Design, Synthesis, and Biological Evaluation of 2-Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors. | Deng, M., et al. 2023. ChemMedChem. 18: e202200664. PMID: 36732891
- PTBP1 enforces ATR-CHK1 signaling determining the potency of CDC7 inhibitors. | Göder, A., et al. 2023. iScience. 26: 106951. PMID: 37378325
- Hornerin mediates phosphorylation of the polo-box domain in Plk1 by Chk1 to induce death in mitosis. | Song, H., et al. 2023. Cell Death Differ. 30: 2151-2166. PMID: 37596441
- Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition. | Sarchi, M., et al. 2024. Blood Cancer Discov. 5: 353-370. PMID: 38856693
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Chk1 Antibody (D-7) | sc-377231 | 200 µg/ml | $322.00 | |||
Chk1 Antibody (D-7): m-IgG1 BP-HRP Bundle | sc-542708 | 200 µg Ab; 20 µg BP | $361.00 |